The Valley Desk

NCT01997333 · Interventional trial

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

Overall registry status Completed

Phase 2

Conditions Metastatic gpNMB Over-expressing Triple Negative Breast Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov